

**ΕΡΑνεΚ 2014-2020**  
**OPERATIONAL PROGRAMME**  
**COMPETITIVENESS • ENTREPRENEURSHIP • INNOVATION**

## "Elevating Greek Startups against COVID 19

The enterprise **PharmaGnose Biotechnology S.A.** based in **Central Greece** Region, has joined the Action "Elevating Greek Startups against COVID 19 " with a total budget of **60 million €**. The Action aims at the support of start-ups included in the National Register of Start-ups "Elevate Greece" in the form of a non-refundable grant as working capital to cover their expenses.

The total budget that the enterprise received as a non-refundable grant is 100.000,00€ and is co-financed by Greece and the European Union - European Regional Development Fund.

**The Public Expenditure is the 100% of the working capital of the year 2019.**

**Through the participation in the Action, the enterprise achieved:**

- ✓ Competitiveness improvement
- ✓ Increase of liquidity
- ✓ Reinforcement of an extrovert business profile
- ✓ Entrepreneurship Reinforcement
- ✓ Creation/ retention of jobs

The support of ΕΡΑνεΚ proved beneficial, not only for the enterprise but for the competitiveness of the national as well as the national economy.



**European Union**  
European Regional  
Development Fund



HELLENIC REPUBLIC  
MINISTRY OF  
DEVELOPMENT AND INVESTMENTS  
SPECIAL SECRETARIAT FOR  
ERDF & CF PROGRAMMES  
MANAGING AUTHORITY OF ΕΡΑνεΚ



**GENERAL SECRETARIAT FOR  
RESEARCH AND INNOVATION**



ανάπτυξη - εργασία - αλληλεγγύη  
**Partnership Agreement  
2014 - 2020**

Co-financed by Greece and the European Union